Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FAA
|
|||
| Former ID |
DIB015887
|
|||
| Drug Name |
Metelimumab
|
|||
| Synonyms |
CAT-192; SL15A-IgG4; Anti-TGF beta 1 antibodies, Genzyme General/Cambridge Antibody Technologies
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Scleroderma [ICD-11: 4A42; ICD-9: 701.0710.1] | Phase 1/2 | [1] | |
| Company |
Cambridge Antibody Technology Group plc; MedImmune
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00043706) Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.